Browsing by Author "Temizhan, Ahmet"

Now showing 1 - 4 of 4

Does cardiologist lead enhanced heart failure education and follow-up program affect cardiovascular mortality rate?: Hit-point
(Lippincott Williams & Wilkins, 2013-11-26) Cavuşoğlu, Yüksel; Zoghi, Mehdi; Eren, Mehmet; Bozcalı, Evin; Kozdağ, Güliz; Şentürk, Tuncay; Alıcık, Güray; Soylu, Korhan; Sarı, İbrahim; Temizhan, Ahmet; Ergene, Oktay; Soran, Özlem; Şentürk, Tuncay; Uludağ Üniversitesi/Tıp Fakültesi.; C-1517-2017
Management of hyperkalemia in heart failure
(Kare Publ, 2021-10-01) Altay, Hakan; Çavuşoğlu, Yüksel; Çelik, Ahmet; Demir, Şerafettin; Kılıçarslan, Barış; Nalbantgil, Sanem; Temizhan, Ahmet; Tokgöz, Bülent; Ural, Dilek; Yıldırımtürk, Özlem; Yılmaz, Mehmet Birhan; Yeşilbursa, Dilek; YEŞİLBURSA, DİLEK; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.
Hyperkalemia is a common electrolyte abnormality in heart failure (HF) that can cause potentially life-threatening cardiac arrhythmias and sudden cardiac death. HF patients with diabetes, chronic kidney disease and older age are at higher risk of hyperkalemia. Moreover, hyperkalemia is also often associated with the use of renin-angiotensin-aldosterone system inhibitors (RAASi) including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists and sacubitril-valsartan. In clinical practice, the occurrence of hyperkalemia is a major concern among the clinicians and often limits RAASi use and/ or lead to dose reduction or discontinuation, thereby reducing their potential benefits for HF. Furthermore, recurrent hyperkalemia is frequent in the long-term and is associated with an increase in hyperkalemia-related hospitalizations. Therefore, management of hyperkalemia has a special importance in HF patients. However, treatment options in chronic management are currently limited. Dietary restriction of potassium is usually ineffective with variable adherence. Sodium polystyrene sulfonate is commonly used, but its effectiveness is uncertain and reported to be associated with intestinal toxicity. New therapeutic options such as potassium binders have been suggested as potentially beneficial agents in the management of hyperkalemia. This document discusses prevalence, predictors and management of hyperkalemia in HF, emphasizing the importance of careful patient selection for medical treatment, uptitration of the doses of RAASi, regular surveillance of potassium and treatment options of hyperkalemia.
Post-discharge heart failure monitoring program in Turkey: Hit-PoinT
(Kare Yayıncılık, 2016-02-19) Çavuşoğlu, Yüksel; Zoghi, Mehdi; Eren, Mehmet; Bozcali, Evin; Kozdağ, Güliz; Alicik, Güray; Soylu, Korhan; Sarı, İbrahim; Berilgen, Rida; Temizhan, Ahmet; Gencer, Erkan; Orhan, Ahmet Lütfü; Polat, Veli; Aktoz, Meryem; Zengin, Halit; Aksoy, Mehmet; Selçuk, Mehmet Timur; Ergene, Oktay; Soran, Özlem; Şentürk, Tunay; Kaderli, Aysel Aydın; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; C-1517-2017; 8342098300; 7801322152
Objective: The aim of this study was to assess the efficacy and feasibility of an enhanced heart failure (HF) education with a 6-month telephone follow- up program in post-discharge ambulatory HF patients. Methods: The Hit-Point trial was a multicenter, randomized, controlled trial of enhanced HF education with a 6-month telephone follow-up program (EHFP) vs routine care (RC) in patients with HF and reduced ejection fraction. A total of 248 patients from 10 centers in various geographical areas were randomized: 125 to EHFP and 123 to RC. Education included information on adherence to treatment, symptom recognition, diet and fluid intake, weight monitoring, activity and exercise training. Patients were contacted by telephone after 1, 3, and 6 months. The primary study endpoint was cardiovascular death. Results: Although all-cause mortality didn't differ between the EHFP and RC groups (p=NS), the percentage of cardiovascular deaths in the EHFP group was significantly lower than in the RC group at the 6-month follow up (5.6% vs. 8.9%, p=0.04). The median number of emergency room visits was one and the median number of all cause hospitalizations and heart failure hospitalizations were zero. Twenty-tree percent of the EHFP group and 35% of the RC group had more than a median number of emergency room visits (p=0.05). There was no significant difference regarding the median number of all-cause or heart failure hospitalizations. At baseline, 60% of patients in EHFP and 61% in RC were in NYHA Class III or IV, while at the 6-month follow up only 12% in EHFP and 32% in RC were in NYHA Class III or IV (p=0.001). Conclusion: These results demonstrate the potential clinical benefits of an enhanced HF education and follow up program led by a cardiologist in reducing cardiovascular deaths and number of emergency room visits with an improvement in functional capacity at 6 months in post-discharge ambulatory HF patients.
Post-discharge heart failure monitorization program in Turkey: Hit-PoinT
(Elsevier Science, 2013-10-29) Çavuşoğlu, Yüksel; Zoghi, Mehdi; Eren, Mehmet; Bozcalı, Evin; Kozdağ, Güliz; Şentürk, Tuncay; Alıcık, Güray; Soylu, Korhan; Sarı, İbrahim; Temizhan, Ahmet; Ergene, Oktay; Soran, Özlem; Şentürk, Tuncay; Uludağ Üniversitesi/Tıp Fakültesi.; C-1517-2017